Journal Mobile Options
Table of Contents
Vol. 118, No. 2-4, 1999
Issue release date: February–April 1999
Int Arch Allergy Immunol 1999;118:98–100

Eosinophil Development and Bone Marrow and Tissue Eosinophils in Atopic Asthma

Robinson D.S. · North J. · Zeibecoglou K. · Ying S. · Meng Q. · Rankin S. · Hamid Q. · Tavernier J. · Kay A.B.
aAllergy and Clinical Immunology and bLeukocyte Biology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK; cMeakins Christie Laboratories, McGill University, Montreal, Canada; dDepartment of Medical Protein Chemistry, Flanders Inter–University Institute for Biotechnology, Gent, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Eosinophils develop from bone marrow (BM) progenitors, and interleukin–5 (IL–5) and eotaxin may act in expansion and mobilisation of BM eosinophils in asthma. Methods: We have examined phenotypic changes as CD34+ cells develop to the eosinophil lineage in vitro, and have evaluated BM eosinophils from asthmatic and control subjects for expression of the eotaxin receptor, CCR3. Results: Acquisition of receptors for IL–5 and CCR3 was an early event in eosinophil development. There were increased CD34+ cells, and mature and immature CCR3+ eosinophils in BM from asthmatics. Conclusion: These data suggest that IL–5 may act early in eosinophil development, and that eotaxin has the capacity to mobilise a BM eosinophil pool in asthma.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Busse WW, Calhoun WF, Sedgwick JD: Mechanism of airway inflammation in asthma. Am Rev Respir Dis 1993;147:S20–S24.

    External Resources

  2. Sehmi R, Wood LJ, Watson R, Foley R, Hamid Q, O’Byrne PM, Denburg JA: Allergen–induced increases in IL–5Rα subunit expression on bone–marrow derived CD34+ cells from asthmatic subjects. J Clin Invest 1997;100: 2466–2475.

    External Resources

  3. Jose PJ, Griffiths Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ: Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1994;179:881–887.
  4. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, Newman W, Gerard C, Mackay CR: Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996;183:2437– 2448.
  5. Sehmi R, Howie K, Sutherland DR, Schragge W, O’Byrne PM, Denburg JA: Increased levels of CD34+ hemopoietic progenitor cells in atopic subjects. Am J Respir Cell Mol Biol 1996;15:645–655.
  6. Collins PD, Marleau S, Griffiths Johnson DA, Jose PJ, Williams TJ: Cooperation between interleukin–5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182:1169–1174.
  7. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler D, Mackay CR, Daugherty BL, Springer MS, Durham S, Williams TJ, Kay AB: Enhanced expression of eotaxin and CCR3 mRNA and protein in atopin asthma. Association with airway hyperresponsiveness and predominant co–localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27:3507–3516.
  8. Shalit M, Sekhsaria S, Mauhorter S, Mahanti S, Malech HL: Early commitment to the eosinophil lineage by cultured human peripheral blood CD34+ cells: Messenger RNA analysis. J Allergy Clin Immunol 1996;98:344– 354.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00